About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2025 Clareo Health. All rights reserved.

Adjuvant CCRT vs CT in Minimal N2 NSCLC | Clinical Trials | Clareo Health

COMPLETEDPhase 2

Adjuvant CCRT vs CT in Minimal N2 NSCLC

A Randomized Phase II Study of Adjuvant Concurrent Chemoradiotherapy vs Chemotherapy Alone in Completely Resected Microscopic N2 Non-small Cell Lung Cancer

NCT01066234•Samsung Medical Center

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Non-small Cell Lung Cancer

Interventions

concurrent chemoradiotherapy

chemotherapy only

Locations

1

South Korea

Locations (1)

Samsung Medical Center

Seoul, South Korea

Key Dates

Start Date

October 23, 2017

Primary Completion Date

January 18, 2021

Completion Date

January 18, 2021

Last Updated

March 22, 2021

Related Studies

RECRUITINGPhase 3

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

RECRUITINGPhase 3

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248

Non-small Cell Lung Cancer

RECRUITINGPhase 2/3

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080

Non-Small Cell Lung Cancer

RECRUITINGPhase 3

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT07195695

Non-small Cell Lung Cancer

RECRUITINGPhase 3

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533

Non-Small Cell Lung Cancer

RECRUITINGPhase 2

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

NCT06731413

Non-Small Cell Lung CancerNSCLC+2 more

View all related studies

Sponsors

Lead Sponsor

Samsung Medical Center

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 22, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions